^
    Back
    Association details:
    Biomarker:EGFR H773_V774insH
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Sci Transl Med
    Title:

    Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

    Excerpt:
    Response to EGFR TKIs of NSCLCs harboring EGFR exon 20 insertion mutations.
    DOI:
    10.1126/scitranslmed.3007205
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Thorac Cancer
    Title:

    Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation

    Published date:
    06/11/2020
    Excerpt:
    In this study, we generated a Ba/F3 cell line expressing EGFR H773_V774 insH mutation and identified a synergistic treatment (EA with erlotinib) that markedly inhibited the viability of Ba/F3-insH cells in vitro and in vivo.
    DOI:
    10.1111/1759-7714.13487